Cardiac amyloidosis: state-of-the-art review

Syed Bukhari

doi:10.26599/1671-5411.2023.05.006

Volume 20 Issue 5

May 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Geriatric Cardiology > 2023 > 20(5): 361-375

Please cite this article as: Bukhari S. Cardiac amyloidosis: state-of-the-art review. J Geriatr Cardiol 2023; 20(5): 361−375. DOI: 10.26599/1671-5411.2023.05.006

Citation:

Please cite this article as: Bukhari S. Cardiac amyloidosis: state-of-the-art review. J Geriatr Cardiol 2023; 20(5): 361−375. DOI: 10.26599/1671-5411.2023.05.006

Please cite this article as: Bukhari S. Cardiac amyloidosis: state-of-the-art review. J Geriatr Cardiol 2023; 20(5): 361−375. DOI: 10.26599/1671-5411.2023.05.006

Citation:

Please cite this article as: Bukhari S. Cardiac amyloidosis: state-of-the-art review. J Geriatr Cardiol 2023; 20(5): 361−375. DOI: 10.26599/1671-5411.2023.05.006

PDF( 843 KB)

Cardiac amyloidosis: state-of-the-art review

doi: 10.26599/1671-5411.2023.05.006

Syed Bukhari^,

1.
Department of Medicine, Temple University Hospital, Philadelphia, PA, USA

More Information

Corresponding author: Syed.Bukhari@tuhs.temple.edu
Publish Date: 2023-05-28

Abstract

Abstract

Cardiac amyloidosis (CA) is caused by deposition of amyloid fibrils in the myocardium and has two main subtypes, transthyretin cardiac amyloidosis (ATTR) and immunoglobulin light chain cardiac amyloidosis (AL). ATTR is further differentiated into wild-type (wtATTR) and hereditary (hATTR), depending on the absence or presence of mutation in the transthyretin gene. The increased recognition of disease with the improvement in diagnostic armamentarium and serendipitous advancements in the therapeutic landscape have changed the status of CA from being a rare and untreatable disease to being a not-so-rare and treatable disease. Both ATTR and AL have certain clinical aspects that can provide early clues for the disease. While electrocardiography followed by echocardiography and subsequently cardiac magnetic resonance can raise suspicion for CA, the definitive diagnosis of ATTR is non-invasively established by bone scintigraphy while that of AL always needs histological confirmation. Severity of CA can be gauged by serum biomarker-based staging of both ATTR and AL. ATTR therapies work by silencing or stabilizing TTR or by degrading amyloid fibrils, while AL is managed with anti-plasma cell therapies and autologous stem cell transplant.

FullText(HTML)

References(100)

References

[1]	Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583−596. doi: 10.1056/NEJMra023144
[2]	Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112: 2047−2060. doi: 10.1161/CIRCULATIONAHA.104.489187
[3]	Masri A, Bukhari S, Eisele YS, et al. Molecular imaging of cardiac amyloidosis. J Nucl Med 2020; 61: 965−970. doi: 10.2967/jnumed.120.245381
[4]	González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36: 2585−2594. doi: 10.1093/eurheartj/ehv338
[5]	Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017; 38: 2879−2887. doi: 10.1093/eurheartj/ehx350
[6]	Maurizi N, Rella V, Fumagalli C, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol 2020; 300: 191−195. doi: 10.1016/j.ijcard.2019.07.051
[7]	Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008; 40: 232−239. doi: 10.1080/07853890701842988
[8]	Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis, 1987-2019. N Engl J Med 2020; 382: 1567−1568. doi: 10.1056/NEJMc1917321
[9]	Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79: 1817−1822. doi: 10.1182/blood.V79.7.1817.1817
[10]	Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 2010; 107: 4188−4193. doi: 10.1073/pnas.0912263107
[11]	Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014; 124: 2325−2332.
[12]	Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016; 68: 1014−1020. doi: 10.1016/j.jacc.2016.06.033
[13]	Pilebro B, Suhr OB, Näslund U, et al. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci 2016; 121: 17−24. doi: 10.3109/03009734.2015.1122687
[14]	Buxbaum J, Jacobson DR, Tagoe C, et al. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol 2006; 47: 1724−1725. doi: 10.1016/j.jacc.2006.01.042
[15]	Reilly MM, Staunton H, Harding AE. Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry 1995; 59: 45−49. doi: 10.1136/jnnp.59.1.45
[16]	Bonaïti B, Olsson M, Hellman U, et al. TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance? Eur J Hum Genet 2010; 18: 948−952. doi: 10.1038/ejhg.2010.36
[17]	Waddington-Cruz M, Wixner J, Amass L, et al. THAOS investigators. Characteristics of patients with late- vs. early-onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurol Ther 2021; 10: 753−766.
[18]	Maurer MS, Hanna M, Grogan M, et al. THAOS Investigators. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 2016; 68: 161−172. doi: 10.1016/j.jacc.2016.03.596
[19]	Dungu JN, Valencia O, Pinney JH, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 2014; 7: 133−142. doi: 10.1016/j.jcmg.2013.08.015
[20]	Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res 2021; 128: 1554−1575. doi: 10.1161/CIRCRESAHA.121.318187
[21]	Bukhari S, Oliveros E, Parekh H, et al. Epidemiology, mechanisms, and management of atrial fibrillation in cardiac amyloidosis. Curr Probl Cardiol 2022; 48: 101571.
[22]	Oye M, Dhruva P, Kandah F, et al. Cardiac amyloid presenting as cardiogenic shock: case series. Eur Heart J Case Rep 2021; 5: ytab252. doi: 10.1093/ehjcr/ytab252
[23]	Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 2000; 109: 181−188. doi: 10.1016/S0002-9343(00)00471-X
[24]	Dorbala S, Vangala D, Bruyere J Jr, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail 2014; 2: 358−367. doi: 10.1016/j.jchf.2014.03.009
[25]	Nitsche C, Scully PR, Patel KP, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol 2021; 77: 128−139.
[26]	Milandri A, Farioli A, Gagliardi C, et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail 2020; 22: 507−515. doi: 10.1002/ejhf.1742
[27]	Sperry BW, Reyes BA, Ikram A, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol 2018; 72: 2040−2050. doi: 10.1016/j.jacc.2018.07.092
[28]	Westin O, Fosbøl EL, Maurer MS et al. Screening for cardiac amyloidosis 5 to 15 years after surgery for bilateral carpal tunnel syndrome. J Am Coll Cardiol 2022; 80: 967−977. doi: 10.1016/j.jacc.2022.06.026
[29]	Maurer MS, Smiley D, Simsolo E, et al. Analysis of lumbar spine stenosis specimens for identification of amyloid. J Am Geriatr Soc 2022; 70: 3538−3548. doi: 10.1111/jgs.17976
[30]	Geller HI, Singh A, Alexander KM, et al. Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. JAMA 2017; 318: 962−963. doi: 10.1001/jama.2017.9236
[31]	Rubin J, Alvarez J, Teruya S, et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid 2017; 24: 226−230.
[32]	Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol 2006; 17: 3458−3471. doi: 10.1681/ASN.2006050460
[33]	Sharma A, Bansal S, Jain R. Unique morphology of intratubular light chain casts in multiple myeloma: the amyloid cast nephropathy. Indian J Pathol Microbiol 2014; 57: 629−631. doi: 10.4103/0377-4929.142712
[34]	Cipriani A, De Michieli L, Porcari A et al. Low QRS voltages in cardiac amyloidosis: clinical correlates and prognostic value. JACC Cardio Oncol 2022; 4: 458−470. doi: 10.1016/j.jaccao.2022.08.007
[35]	Cyrille NB, Goldsmith J, Alvarez J, et al. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 2014; 114: 1089−1093. doi: 10.1016/j.amjcard.2014.07.026
[36]	Dungu J, Sattianayagam PT, Whelan CJ, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J 2012; 164: 72−79. doi: 10.1016/j.ahj.2012.04.013
[37]	Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005; 95: 535−537. doi: 10.1016/j.amjcard.2004.10.028
[38]	Das MK, Khan B, Jacob S et al. Significance of a fragmented QRS complex versus a Q wave in patients with coronary artery disease. Circulation 2006; 113: 2495−2501. doi: 10.1161/CIRCULATIONAHA.105.595892
[39]	González-López E, Gagliardi C, Dominguez F, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J 2017; 38: 1895−1904. doi: 10.1093/eurheartj/ehx043
[40]	Falk RH, Alexander KM, Liao R, et al. AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 2016; 68: 1323−1341. doi: 10.1016/j.jacc.2016.06.053
[41]	Nagy D, Révész K, Peskó G, et al. Cardiac amyloidosis with normal wall thickness: prevalence, clinical characteristics and outcome in a retrospective analysis. Biomedicines 2022; 10: 1765. doi: 10.3390/biomedicines10071765
[42]	Vermeer AMC, Janssen A, Boorsma PC, et al. Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy. Amyloid 2017; 24: 87−91.
[43]	López-Sainz Á, de Haro-Del Moral FJ, Dominguez F, et al. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders. Amyloid 2019; 26: 156−163.
[44]	Pagourelias ED, Mirea O, Duchenne J, et al. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging 2017; 10: e005588.
[45]	Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012; 98: 1442−1448. doi: 10.1136/heartjnl-2012-302353
[46]	Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111: 186−193. doi: 10.1161/01.CIR.0000152819.97857.9D
[47]	Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015; 132: 1570−1579. doi: 10.1161/CIRCULATIONAHA.115.016567
[48]	Yang L, Krefting I, Gorovets A, et al. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration. Radiology 2012; 265: 248−253. doi: 10.1148/radiol.12112783
[49]	Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013; 6: 488−497. doi: 10.1016/j.jcmg.2012.11.013
[50]	Banypersad SM, Fontana M, Maestrini V, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J 2015; 36: 244−251. doi: 10.1093/eurheartj/ehu444
[51]	Martinez-Naharro A, Kotecha T, Norrington K, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging 2019; 12: 810−819. doi: 10.1016/j.jcmg.2018.02.006
[52]	Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2013; 6: 34−39.
[53]	Martinez-Naharro A, Abdel-Gadir A, Treibel TA, et al. CMR-verified regression of cardiac AL amyloid after chemotherapy. JACC Cardiovasc Imaging 2018; 11: 152−154. doi: 10.1016/j.jcmg.2017.02.012
[54]	Kotecha T, Martinez-Naharro A, Treibel TA, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol 2018; 71: 2919−2931. doi: 10.1016/j.jacc.2018.03.536
[55]	Rapezzi C, Gagliardi C, Milandri A. Analogies and disparities among scintigraphic bone tracers in the diagnosis of cardiac and non-cardiac ATTR amyloidosis. J Nucl Cardiol 2019; 26: 1638−1641. doi: 10.1007/s12350-018-1235-6
[56]	Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol 2016; 25: 413−417. doi: 10.1016/j.carpath.2016.07.001
[57]	Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46: 1076−1084. doi: 10.1016/j.jacc.2005.05.073
[58]	Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133: 2404−2412. doi: 10.1161/CIRCULATIONAHA.116.021612
[59]	Bokhari S, Castaño A, Pozniakoff T, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013; 6: 195−201. doi: 10.1161/CIRCIMAGING.112.000132
[60]	Masri A, Bukhari S, Ahmad S, et al. Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging 2020; 13: e010249. doi: 10.1161/CIRCIMAGING.119.010249
[61]	Falk RH, Lee VW, Rubinow A, et al. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol 1983; 51: 826−830. doi: 10.1016/S0002-9149(83)80140-4
[62]	Musumeci MB, Cappelli F, Russo D, et al. Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis. JACC Cardiovasc Imaging 2020; 13: 1314−1321. doi: 10.1016/j.jcmg.2019.10.015
[63]	Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J 2004; 147: 919−923. doi: 10.1016/j.ahj.2003.09.020
[64]	Holzmann M, Nicko A, Kühl U, et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation 2008; 118: 1722−1728. doi: 10.1161/CIRCULATIONAHA.107.743427
[65]	Guy CD, Jones CK. Abdominal fat pad aspiration biopsy for tissue confirmation of systemic amyloidosis: specificity, positive predictive value, and diagnostic pitfalls. Diagn Cytopathol 2001; 24: 181−185. doi: 10.1002/1097-0339(200103)24:3<181::AID-DC1037>3.0.CO;2-D
[66]	Takashio S, Yamamuro M, Izumiya Y, et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail 2018; 5: 27−35.
[67]	Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018; 39: 2799−2806. doi: 10.1093/eurheartj/ehx589
[68]	Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751−3757. doi: 10.1200/JCO.2004.03.029
[69]	Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989−995. doi: 10.1200/JCO.2011.38.5724
[70]	Gilstrap LG, Dominici F, Wang Y, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail 2019; 12: e005407. doi: 10.1161/CIRCHEARTFAILURE.118.005407
[71]	Sperry BW, Saeed IM, Raza S, et al. Increasing rate of hospital admissions in patients with amyloidosis (from the National Inpatient Sample). Am J Cardiol 2019; 124: 1765−1769. doi: 10.1016/j.amjcard.2019.08.045
[72]	Chan N, Hanna M, Maurer MS. The Wiggers Diagram: hemodynamic changes in cardiac amyloidosis. J Card Fail 2023; 29: 217−219. doi: 10.1016/j.cardfail.2022.06.008
[73]	Gertz MA, Falk RH, Skinner M, et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 1985; 55: 1645. doi: 10.1016/0002-9149(85)90995-6
[74]	Gertz MA, Skinner M, Connors LH, et al. Selective binding of nifedipine to amyloid fibrils. Am J Cardiol 1985; 55: 1646. doi: 10.1016/0002-9149(85)90996-8
[75]	Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981; 63: 1285−1288. doi: 10.1161/01.CIR.63.6.1285
[76]	Muchtar E, Gertz MA, Kumar SK, et al. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid 2018; 25: 86−92. doi: 10.1080/13506129.2018.1449744
[77]	Bukhari S, Khan SZ, Bashir Z. Atrial fibrillation, thromboembolic risk, and anticoagulation in cardiac amyloidosis: a review. J Card Fail 2023; 29: 76−86. doi: 10.1016/j.cardfail.2022.08.008
[78]	Bukhari S, Barakat AF, Eisele YS, et al. Prevalence of atrial fibrillation and thromboembolic risk in wild-type transthyretin amyloid cardiomyopathy. Circulation 2021; 143: 1335−1337. doi: 10.1161/CIRCULATIONAHA.120.052136
[79]	El-Am EA, Dispenzieri A, Melduni RM, et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol 2019; 73: 589−597.
[80]	Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145: e876−e894.
[81]	Chung FP, Lin YJ, Kuo L, et al. Catheter ablation of ventricular tachycardia/fibrillation in a patient with right ventricular amyloidosis with initial manifestations mimicking arrhythmogenic right ventricular dysplasia/cardiomyopathy. Korean Circ J 2017; 47: 282−285. doi: 10.4070/kcj.2016.0328
[82]	Lin G, Dispenzieri A, Kyle R, et al. Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 2013; 24: 793−798. doi: 10.1111/jce.12123
[83]	Higgins AY, Annapureddy AR, Wang Y, et al. Survival following implantable cardioverter-defibrillator implantation in patients with amyloid cardiomyopathy. J Am Heart Assoc 2020; 9: e016038. doi: 10.1161/JAHA.120.016038
[84]	Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018; 15: e73−e189. doi: 10.1016/j.hrthm.2017.10.036
[85]	Donnellan E, Wazni OM, Saliba WI, et al. Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis. Am J Cardiol 2020; 128: 140−146. doi: 10.1016/j.amjcard.2020.05.021
[86]	Rehorn MR, Loungani RS, Black-Maier E, et al. Cardiac implantable electronic devices: a window into the evolution of conduction disease in cardiac amyloidosis. JACC Clin Electrophysiol 2020; 6: 1144−1154. doi: 10.1016/j.jacep.2020.04.020
[87]	Donnellan E, Wazni OM, Saliba WI, et al. Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol 2019; 30: 2427−2432. doi: 10.1111/jce.14180
[88]	Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494−498. doi: 10.1038/35078107
[89]	Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11−21. doi: 10.1056/NEJMoa1716153
[90]	Crooke ST, Wang S, Vickers TA, et al. Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol 2017; 35: 230−237. doi: 10.1038/nbt.3779
[91]	Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 22−31. doi: 10.1056/NEJMoa1716793
[92]	Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379: 1007−1016. doi: 10.1056/NEJMoa1805689
[93]	Berk JL, Suhr OB, Obici L, et al. Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy:a randomized clinical trial. JAMA 2013; 310: 2658−2667.
[94]	Sekijima Y, Tojo K, Morita H, et al. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid 2015; 22: 79−83. doi: 10.3109/13506129.2014.997872
[95]	Penchala SC, Connelly S, Wang Y, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A 2013; 110: 9992−9997. doi: 10.1073/pnas.1300761110
[96]	Judge DP, Heitner SB, Falk RH, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 2019; 74: 285−295. doi: 10.1016/j.jacc.2019.03.012
[97]	Karlstedt E, Jimenez-Zepeda V, Howlett JG, et al. Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis. J Card Fail 2019; 25: 147−153. doi: 10.1016/j.cardfail.2019.01.006
[98]	Wixner J, Pilebro B, Lundgren HE, et al. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis. Amyloid 2017; 24: 78−79.
[99]	Hasib Sidiqi M, Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. Blood Cancer J 2021; 11: 90. doi: 10.1038/s41408-021-00483-7
[100]	Dispenzieri A, Buadi F, Kumar SK, et al. Treatment of immunoglobulin light chain amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc 2015; 90: 1054−1081. doi: 10.1016/j.mayocp.2015.06.009